Navigation Links
ADVENTRX to Present Complete ANX-530 Pharmacokinetic Data at the 2008 American Association for Cancer Research Annual Meeting
Date:2/7/2008

SAN DIEGO, Feb. 7 /PRNewswire-FirstCall/ -- ADVENTRX Pharmaceuticals, Inc. (Amex: ANX), announced today that complete pharmacokinetic data from the Company's marketing-enabling bioequivalence clinical study of ANX-530 (vinorelbine emulsion) has been accepted for presentation at the 2008 American Association for Cancer Research (AACR) Annual Meeting, which takes place April 12 - 16, 2008 in San Diego, CA.

The poster presentation entitled "Pharmacokinetic equivalence observed between an emulsion formulation of vinorelbine (ANX-530) and vinorelbine solution in a clinical study of patients with advanced cancer," is scheduled to be presented on April 13, 2008.

ADVENTRX recently completed a marketing-enabling bioequivalence clinical study of ANX-530. The primary endpoint in the study was met, with pharmacokinetic equivalence observed between ANX-530 and the reference drug Navelbine(R). Furthermore, ANX-530 demonstrated a statistically significant reduction in injection site reactions when compared to Navelbine. Presentation of complete safety results including injection site reactions, have been submitted for presentation at an upcoming oncology conference. ADVENTRX intends to submit to the U.S. Food and Drug Administration (FDA) a Section 505(b)(2) New Drug Application (NDA) for ANX-530 in the fourth quarter of 2008.

About ANX-530 (vinorelbine emulsion)

ANX-530 is designed to reduce the incidence and severity of injection site reactions from intravenous delivery of vinorelbine tartrate. Vinorelbine tartrate works by disrupting microtubule formation and is a member of the vinca alkaloid class of antineoplastic agents. Vinorelbine is indicated as a single agent or in combination with cisplatin for treatment of advanced
'/>"/>

SOURCE ADVENTRX Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. ADVENTRX Announces Consolidation of Clinical and Management Positions
2. ADVENTRX Pharmaceuticals Reports Third Quarter 2007 Financial Results
3. ADVENTRX Appoints Vice President of Commercialization
4. ADVENTRX Pharmaceuticals to Present at the 2007 BIOInvestor Forum
5. ADVENTRX to Present ANX-514 Preclinical Data at 2007 AACR-NCI-EORTC International Conference
6. ADVENTRX Pharmaceuticals to Present at the 2007 UBS Global Life Sciences Conference
7. ADVENTRX Pharmaceuticals to Present at the ThinkEquity Partners Fifth Annual Growth Conference
8. ADVENTRX Announces ANX-514 Clinical Development Plan Affirmed by the FDA
9. ADVENTRX Pharmaceuticals to Present at the 20th Annual Bear Stearns Healthcare Conference
10. ADVENTRX Pharmaceuticals to Present at the 2007 Thomas Weisel Partners Healthcare Conference
11. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/24/2015)... (PRWEB) April 24, 2015 DryLet, ... use in applications such as animal waste reduction, ... oil reduction in wastewater treatment plants and restaurant ... exhibitor at the National Restaurant Association’s NRA Show ... , Representatives of the company will be available ...
(Date:4/24/2015)... April 24 , 2015 PAREXEL International ... services provider, today announced that Partnerships in Clinical Trials ... Management, the 2015 Clinical Innovator of the Year.  The ... team for the Company,s Perceptive MyTrials ® Data-Driven ... Thursday night during the 2015 Partnership Awards in ...
(Date:4/23/2015)... , April 23, 2015 /CNW/ - A new ... packaging award from North America,s ... Competitor Comparison won Silver in the "Sustainability, service" ... The Brandcheck "Competitor Comparison" is a service ... North American and Global peers. This benchmarking process ...
(Date:4/23/2015)... Follow us on LinkedIn ... of genetic tests that determine individual susceptibility to ... Huntington's disease, and Alzheimer's disease. Predictive diagnostics are ... interaction in diseased tissue/cells to understand and determine ... response to treatment, such as in the numerous ...
Breaking Biology Technology:DryLet to Showcase Bio-React at the National Restaurant Association’s NRA Show 2015 May 16-19, 2015 in Chicago, Illinois 2PAREXEL Honored With 2015 Clinical Innovator Of The Year Award From Partnerships In Clinical Trials 2PAREXEL Honored With 2015 Clinical Innovator Of The Year Award From Partnerships In Clinical Trials 3PAREXEL Honored With 2015 Clinical Innovator Of The Year Award From Partnerships In Clinical Trials 4PAREXEL Honored With 2015 Clinical Innovator Of The Year Award From Partnerships In Clinical Trials 5Increasing Disease Prevalence & Focus on Preventive Healthcare Drive the Predictive Diagnostics Market, According to a New Report by Global Industry Analysts, Inc. 2Increasing Disease Prevalence & Focus on Preventive Healthcare Drive the Predictive Diagnostics Market, According to a New Report by Global Industry Analysts, Inc. 3
... 21, 2011 United Therapeutics Corporation (Nasdaq: ... its FREEDOM-C(2) registration trial was completed on March ... multi-center, international, double-blind, randomized, placebo-controlled study of a ... in pulmonary arterial hypertension (PAH) patients receiving an ...
... Paul Braun,s lab look like any others, but they ... three-dimensional nanostructure for battery cathodes that allows for dramatically ... The researchers, findings will be published in the March ... Nanotechnology. Aside from quick-charge consumer electronics, batteries ...
... 18, 2011 Driving value for customers is critical to ... points between a customer and an organization, there has to ... an organization to succeed in the marketplace. ... Practices, LLC., noted in this month,s special issue of PharmaVoice ...
Cached Biology Technology:United Therapeutics Corporation Completes Enrollment of FREEDOM-C(2) Trial 2Batteries charge quickly and retain capacity, thanks to new structure 2Batteries charge quickly and retain capacity, thanks to new structure 3Best Practices, LLC Showcases Its Expertise in Customer Relationship Management 2
(Date:4/6/2015)... Apr. 6, 2015 NXT-ID, Inc. (NASDAQ: ... authentication company focused on the growing mobile commerce ... patent 62/143028 for MINIATURE, MULTI-PURPOSE ANTENNA ... NXT-ID introduces a new revolutionary method ... surrounds the use of miniature antenna modules for ...
(Date:4/1/2015)... , Apr. 1, 2015  NXT-ID, Inc. (NASDAQ: ... company focused on the growing mobile commerce market, announces ... smart wallets is underway to early access pre-order customers. ... includes usage at retail outlets including Walmart, Target, AT&T, ... report Wocket was accepted at all outlets and very ...
(Date:3/26/2015)... March 26, 2015 The Granite ... recreation and athletic club, today announced it has implemented ... freedom of movement for members and staff, while restricting ... comprehensive process, we selected FST,s IMID Access system because ... for our members and staff, in addition to unparalleled ...
Breaking Biology News(10 mins):NXT-ID Patents Miniature, Low Power Wireless Magnetic Stripe 2NXT-ID Patents Miniature, Low Power Wireless Magnetic Stripe 3NXT-ID Patents Miniature, Low Power Wireless Magnetic Stripe 4NXT-ID Reports Second Shipment of Wocket Smart Wallets Underway to Early Access Pre-order Customers and Provides User Feedback 2NXT-ID Reports Second Shipment of Wocket Smart Wallets Underway to Early Access Pre-order Customers and Provides User Feedback 3NXT-ID Reports Second Shipment of Wocket Smart Wallets Underway to Early Access Pre-order Customers and Provides User Feedback 4Granite Club First Private Club in North America to Implement FST Biometrics Secure Access Solution, as Part of Multi-million Dollar Expansion 2
... the frontal cortex in adults, researchers have shown that this ... actions. , It has been known for over 100 ... left frontal cortex, he or she often suffers difficulties in ... impairments, it has been difficult for researchers to test the ...
... high levels of antibodies against the Epstein-Barr virus, the ... likely to develop multiple sclerosis 15 to 20 years ... will appear in the June 2006 print issue of ... Researchers have long suspected that external factors may influence ...
... The cholesterol-lowering medications called statins do not appear to ... to a meta-analysis of previous studies in the January ... that statins reduce the risk of developing cancer, the ... "Statins have been studied in numerous large-scale, randomized, ...
Cached Biology News:Big hips, big belly? It's in your genes, Joslin-led study shows 2Statins have neutral effect on risk of cancer 2
...
Smac/DIABLO (CT) - IgG for Western Blotting, Host: Rabbit Family: Smac/DIABLO...
Mouse monoclonal [ICRF 44] to Integrin alpha M...
... The new Finnpipette Focus ... tip cone for pipetting from ... other narrow and long necked ... that whatever volume you select, ...
Biology Products: